Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 27, 2015 12:52 AM ET

Health Care Technology

Company Overview of Definiens AG

Company Overview

Definiens AG develops and offers intelligent software solutions for digital image analysis, knowledge management, and other simulation activities for life sciences and clinical research companies. The company's products include eCognition, which analyzes geographic information; and Ikonos that analyzes and distributes space images. The company was formerly known as Delphi2 Creative Technologies GmbH and changed its name to Definiens AG in September 2000. Definiens AG was founded in 1994 and is based in Munich, Germany. As of November 4, 2014, Definiens AG operates as a subsidiary of MedImmune, LLC.

Bernhard-Wicki-Straße 5

Munich,  80339


Founded in 1994


49 89 2311800


49 89 23118090

Key Executives for Definiens AG

Chief Executive Officer
Founder, Chief Technology Officer, Member of Executive Board and Director
Chief Financial Officer and Member of the Executive Board
Chief Operating Officer and Member of the Executive Board
Compensation as of Fiscal Year 2014.

Definiens AG Key Developments

Definiens AG Secures EUR 15 Million Financing for Tissue Phenomics-Based Cancer Diagnostics; Appoints Rainer Strohmenger to the Board of Directors

Definiens AG announced that it has closed a round of financing for EUR 15 million. The round was led by Wellington Partners, a leading pan-European venture capital firm. Gilde Healthcare co-led the financing round and was joined by other existing investors Cipio Partners and TVM Capital in the financing. The new funds will allow Definiens to grow its global business in digital pathology image analysis and expand into digital tissue diagnostics. Major investments will be made in executing the company's Tissue Phenomics strategy, enabling partnerships with leading medical centers and pharmaceutical companies to advance the diagnosis and treatment of cancer. In conjunction with the financing, Dr. Rainer Strohmenger, General Partner and Managing Director for Wellington, will join Definiens' Board of Directors.

Definiens Signs Agreement with Clarient Diagnostic Services, Inc. to Offer Validated Solutions for Routine Clinical Pathology Testing

Definiens announced the signing of an agreement with Clarient Diagnostic Services Inc.- which extends the use of Definiens' automated image analysis software and solutions in Clarient's validated clinical applications for immunohistochemistry testing in breast cancer. Definiens' proprietary Cognition Network Technology(R) is core to automatically classify and quantitate key tissue features as part of Clarient's Scope IA Platform offering to its pathology customers.

Definiens AG Presents at BioJapan 2013 World Business Forum, Oct-09-2013

Definiens AG Presents at BioJapan 2013 World Business Forum, Oct-09-2013 . Venue: Pacifico Yokohama, Yokohama, Japan.

Similar Private Companies By Industry

Company Name Region
ADG - Apotheken Dienstleistungsgesellschaft mbH Europe
Cymed AG Europe
Werum Software & Systems AG Europe
Allgeier Medical IT GmbH Europe
Waldbrenner AG Europe

Recent Private Companies Transactions

November 4, 2014
Private Placement
June 23, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Definiens AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at